KIT and cancer: KIT (CD117)+ ovarian cancer cells manifest a striking higher tumorigenic activity than CD117-negative cancer cells and were able to generate the original tumor heterogeneity, suggesting self-renewal and multi-linage differentiation capabilities of these cells [53].